TPO and autoimmune thrombocytopenic purpura: Moreover, herombopag, a second-generation TPO agonist, which has been shown to be effective in post-allogeneic hematopoietic cell transplantation thrombocytopenia management, is being investigated in children with chronic and persistent ITP (NCT05685420) [119,120].